Home> Products> core symptoms

{ "products": [ { "_id": "699bfe45e844b0fb29d2bbad", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Sitagliptin 100 Pioglitazone 15 Metformin 500", "description": "Product Name: ST GLIPTIN 3D 500\nComposition: Sitagliptin 100 mg + Pioglitazone 15 mg + Metformin 500 mg\n\nST GLIPTIN 3D 500 is a scientifically formulated triple-combination oral antidiabetic tablet designed to help manage Type 2 Diabetes Mellitus effectively. This advanced formulation combines the proven benefits of Sitagliptin, Pioglitazone, and Metformin to provide comprehensive glycemic control through three complementary mechanisms of action.\n\nThis triple therapy approach is especially beneficial for patients whose blood glucose levels are not adequately controlled with dual therapy or monotherapy. ST GLIPTIN 3D 500 is developed to address multiple metabolic defects associated with Type 2 diabetes, ensuring better long-term glucose management and improved patient outcomes.\n\nProduct Description\n\nST GLIPTIN 3D 500 is an oral antidiabetic medication that works by targeting different physiological pathways involved in glucose regulation:\n\nSitagliptin 100 mg enhances incretin hormone levels, which increase insulin release and decrease glucagon secretion in a glucose-dependent manner.\n\nPioglitazone 15 mg improves insulin sensitivity in muscle and adipose tissues, allowing the body to use insulin more effectively.\n\nMetformin 500 mg reduces hepatic glucose production and improves peripheral glucose uptake.\n\nBy combining these three well-established agents into a single tablet, ST GLIPTIN 3D 500 simplifies diabetes management while improving adherence and therapeutic efficiency.\n\nUses of ST GLIPTIN 3D 500\n\nST GLIPTIN 3D 500 is primarily indicated for:\n\nManagement of Type 2 Diabetes Mellitus\n\nImproving glycemic control in adults\n\nPatients inadequately controlled on metformin alone\n\nIndividuals requiring triple oral therapy\n\nReducing fasting and postprandial blood glucose levels\n\nSupporting long-term HbA1c reduction\n\nIt is typically prescribed alongside lifestyle modifications such as a healthy diet, regular exercise, and weight management.\n\nHow ST GLIPTIN 3D 500 Works\n\nType 2 diabetes is characterized by insulin resistance, decreased insulin secretion, and excessive hepatic glucose production. ST GLIPTIN 3D 500 addresses all three core defects:\n\nEnhances insulin secretion (Sitagliptin) – Works in a glucose-dependent manner, reducing risk of hypoglycemia.\n\nImproves insulin sensitivity (Pioglitazone) – Helps the body respond better to insulin.\n\nReduces glucose production (Metformin) – Decreases sugar release from the liver.\n\nThis comprehensive mechanism makes ST GLIPTIN 3D 500 a powerful therapeutic option for sustained glycemic control.\n\nKey Benefits of ST GLIPTIN 3D 500\n1. Triple Mechanism Advantage\n\nCombines three different classes of antidiabetic agents for broader and more effective blood sugar management.\n\n2. Improved HbA1c Reduction\n\nHelps significantly lower HbA1c levels when compared to monotherapy.\n\n3. Reduced Pill Burden\n\nThree medications in one tablet improve patient compliance and convenience.\n\n4. Better Postprandial Control\n\nHelps manage blood glucose spikes after meals.\n\n5. Insulin Sensitivity Enhancement\n\nPioglitazone improves peripheral glucose utilization.\n\n6. Lower Risk of Hypoglycemia\n\nSitagliptin works in a glucose-dependent manner, minimizing low blood sugar risk when used appropriately.\n\n7. Suitable for Long-Term Management\n\nDesigned for chronic use under medical supervision.\n\nDosage and Administration\n\nThe dosage should be taken strictly as prescribed by a healthcare professional.\n\nUsually administered once daily with meals to reduce gastrointestinal discomfort.\n\nSwallow the tablet whole with water.\n\nDo not crush or chew unless directed by a doctor.\n\nRegular monitoring of blood glucose and HbA1c levels is recommended during therapy.\n\nPossible Side Effects\n\nLike all medications, ST GLIPTIN 3D 500 may cause side effects, although not everyone experiences them.\n\nCommon Side Effects:\n\nNausea\n\nDiarrhea\n\nStomach discomfort\n\nHeadache\n\nUpper respiratory symptoms\n\nLess Common but Important:\n\nWeight gain (associated with Pioglitazone)\n\nFluid retention or edema\n\nLow blood sugar (when combined with other antidiabetic agents)\n\nVitamin B12 deficiency (long-term Metformin use)\n\nRare but Serious:\n\nLactic acidosis (rare, associated with Metformin)\n\nPancreatitis (rare, associated with Sitagliptin)\n\nLiver function abnormalities\n\nPatients should immediately consult a healthcare provider if they experience severe abdominal pain, persistent vomiting, unusual swelling, or breathing difficulties.\n\nPrecautions and Warnings\n\nNot recommended for Type 1 diabetes.\n\nUse cautiously in patients with renal impairment.\n\nLiver function monitoring may be required.\n\nAvoid excessive alcohol consumption.\n\nInform your doctor about any existing heart conditions.\n\nPregnant or breastfeeding women should use this medication only if clearly advised by a healthcare professional.\n\nStorage Instructions\n\nStore below 25°C in a dry place.\n\nKeep away from direct sunlight.\n\nKeep out of reach of children.\n\nWhy Choose ST GLIPTIN 3D 500?\n\nST GLIPTIN 3D 500 stands out as a comprehensive diabetes management solution by combining three powerful and clinically established molecules in one convenient tablet. It is particularly beneficial for patients who require intensified glycemic control without increasing pill burden.\n\nThe triple therapy model helps target multiple metabolic dysfunctions simultaneously, offering better blood glucose stability throughout the day. When used as part of a complete diabetes management plan—including diet, exercise, and routine monitoring—ST GLIPTIN 3D 500 can significantly enhance quality of life and reduce long-term complications associated with uncontrolled diabetes.\n\nConclusion\nST GLIPTIN 3D 500 (Sitagliptin 100 mg + Pioglitazone 15 mg + Metformin 500 mg) represents a modern, evidence-based approach to managing Type 2 Diabetes Mellitus. By addressing insulin resistance, impaired insulin secretion, and excessive glucose production, it provides comprehensive and sustained glycemic control.", "price": 222.0, "discountamount": 67.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2311, "imageuri": "https://productimages.withfloats.com/actual/699bfe47d849febb9bcc2d46.png", "tileimageuri": "https://productimages.withfloats.com/tile/699bfe47d849febb9bcc2d46.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-02-23T07:14:13.494Z", "updatedon": "2026-03-13T11:04:02.141Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/sitagliptin-100-pioglitazone-15-metformin-500/2311", "availableunits": -1.0, "iscodavailable": true, "isprepaidonlineavailable": true, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ST GLIPTIN 3D 500", "category": "DIABETIC RANGE", "tags": [ "Sitagliptin 100 Pioglitazone 15 Metformin 500 tablet uses", "Sitagliptin Pioglitazone Metformin triple therapy dosage", "Sitagliptin 100 mg Pioglitazone 15 mg Metformin 500 mg benefits", "Triple combination tablet for type 2 diabetes control", "Sitagliptin Pioglitazone Metformin side effects in adults", "How to take Sitagliptin Pioglitazone Metformin tablet", "Sitagliptin Metformin Pioglitazone price in India", "Buy Sitagliptin 100 Pioglitazone 15 Metformin 500 online", "Order Sitagliptin Pioglitazone Metformin tablets", "Sitagliptin 100 Pioglitazone 15 Metformin 500 price", "Sitagliptin triple combination bulk purchase" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "694e56c05837f90c86a7eb8c", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "empagliflozin linagliptin and metformin", "description": "LINALIGIP EMPAMET (Empagliflozin, Linagliptin, and Metformin Hydrochloride ER Tablets) stands out as a comprehensive triple therapy for adults with type 2 diabetes mellitus, combining three synergistic agents to tackle hyperglycemia from multiple angles. This once-daily extended-release formulation simplifies adherence while delivering robust glycemic control, weight management, and cardiovascular protection. Patients often seek it for its convenience in managing blood sugar levels when diet, exercise, and single agents fall short.\n​\n\nProduct Description and Composition\nLINALIGIP EMPAMET features Empagliflozin (typically 10-25mg), Linagliptin (5 mg), and Metformin Hydrochloride ER (up to 1000mg) in a single tablet, designed for prolonged release to minimize gastrointestinal upset. Empagliflozin, an SGLT2 inhibitor, blocks glucose reabsorption in the kidneys, promoting its excretion via urine. Linagliptin, a DPP-4 inhibitor, enhances incretin hormones like GLP-1 to boost insulin secretion and suppress glucagon. Metformin ER reduces hepatic glucose production and improves insulin sensitivity without hypoglycemia risk.\n​\n\nThis unique blend from Steris Healthcare ensures steady drug delivery over 24 hours, reducing peak-trough fluctuations for stable HbA1c reductions of 1.5-2.0%. The extended-release metformin coats the tablet core, dissolving gradually in the intestines for better tolerability compared to immediate-release forms. Ideal for Indian patients facing rising diabetes prevalence, it addresses insulin resistance, postprandial spikes, and caloric overload holistically.\n​\n\nMechanism of Action\nThe triple mechanism targets key diabetes pathways: Empagliflozin inhibits SGLT2 in proximal renal tubules, lowering blood glucose by 70-90g daily through glycosuria, independent of insulin. Linagliptin selectively binds DPP-4, prolonging GLP-1 and GIP activity to stimulate glucose-dependent insulin release from beta cells and curb glucagon-mediated gluconeogenesis. Metformin activates AMPK in hepatocytes, inhibiting gluconeogenesis while enhancing peripheral glucose uptake.\n​\n\nSynergy amplifies effects—SGLT2 inhibition provides insulin-independent control, DPP-4 boosts prandial responses, and metformin tackles fasting hyperglycemia—resulting in complementary HbA1c drops without overlapping toxicities. Clinical data show this combination yields superior efficacy over dual therapies, with added osmotic diuresis aiding fluid balance.\n​\n\nUses and Indications\nLINALIGIP EMPAMET treats type 2 diabetes in adults, as adjunct to diet and exercise, especially when metformin alone or dual therapy inadequately controls glycemia. Primary uses include newly diagnosed patients needing intensification, those with obesity (due to weight loss from glycosuria), and high-risk cardiovascular profiles benefiting from empagliflozin's heart protection. It excels in managing postprandial hyperglycemia, fasting glucose, and preventing complications like nephropathy.\n​\n\nPrescribed for patients intolerant to other agents or requiring simplified regimens, it suits Indian demographics with high metabolic syndrome rates. Not for type 1 diabetes or ketoacidosis; renal function (eGFR >45 mL/min) guides initiation.\n​\n\nKey Benefits\nLINALIGIP EMPAMET offers multifaceted advantages for long-term diabetes management:\n\nSuperior Glycemic Control: Achieves 1.8% HbA1c reduction in trials, outperforming monotherapies by targeting multiple defects.\n​\n\nWeight Loss: Empagliflozin induces 3-5kg loss via caloric excretion, countering metformin's neutral effect.\n​\n\nCardiovascular and Renal Protection: Reduces major adverse cardiac events (MACE) by 14% and slows CKD progression, per EMPA-REG outcomes.\n​\n\nLow Hypoglycemia Risk: Glucose-dependent actions of linagliptin and empagliflozin minimize lows, unlike sulfonylureas.\n​\n\nConvenience: Single-tablet ER dosing improves compliance, vital for busy lifestyles in Jaipur and beyond.\n​\n\nBlood Pressure Reduction: Mild diuretic effect lowers systolic BP by 3-5 mmHg.\n​\n\nThese benefits enhance quality of life, reducing fatigue, neuropathy risks, and healthcare costs.\n\nSide Effects\nCommon side effects mirror individual components but occur less due to synergy:\n\nGastrointestinal: Metformin ER causes less nausea/diarrhea (10-15%) than IR forms; titrate slowly.\n​\n\nGenitourinary: Empagliflozin raises UTI/genital mycotic infection risk (5-10%), managed with hygiene.\n​\n\nVolume Depletion: Orthostatic hypotension in 2-3%, especially with diuretics.\n​\n\nSerious effects include lactic acidosis (rare, <1/100,000 with metformin in eGFR >30), ketoacidosis (euglycemic, 0.1%), and acute kidney injury. Monitor for dehydration, pancreatitis signs, or bullous pemphigoid with linagliptin. Hypersensitivity rash or bone fractures warrant discontinuation.\n​\n\nSide Effect Category\tFrequency\tManagement\nNausea and Diarrhea\tCommon (10%)\tTake with food, slow titration \n​\nUTI/Mycotic Infections\tCommon (7%)\tHydration, antifungals \n​\nHypoglycemia\tRare (<2%)\tWith insulin, dose adjust \n​\nLactic Acidosis\tVery Rare.\tAvoid in renal/hepatic failure \n​\nKetoacidosis\tRare (0.1%)\tCheck ketones if nausea \n​\nDosage and Administration\nStart with Empagliflozin 10mg/Linagliptin 5mg/Metformin ER 1000mg once daily with morning meal to optimize absorption and reduce GI effects. Titrate metformin to 2000mg max based on tolerance; empagliflozin to 25mg if needed. Swallow whole; no crushing. Adjust for renal impairment (eGFR 30-45: max metformin 1000mg; <30 contraindicated). Elderly start low due to volume sensitivity.\n​\n\nMissed dose: Take soon if less than 12 hours late; skip otherwise. Discontinue pre-surgery or contrast use.\n\nPrecautions and Warnings\nAssess eGFR before and 3-6 months after initiation; hold if <45. Caution in dehydration, heart failure, or liver disease risks lactic acidosis. Educate on ketoacidosis symptoms (nausea, fatigue) despite normal glucose. Avoid excessive alcohol; monitor BP in hypertensives. Pregnancy category D—use insulin instead. Breastfeeding is contraindicated.\n​\n\nDrug interactions: Adding sulfonylureas/insulin heightens hypoglycemia; rifampin reduces linagliptin levels; ritonavir boosts empagliflozin exposure.\n\nFrequently Asked Questions\nWhat is LINALIGIP EMPAMET used for?\nControls type 2 diabetes via triple action on glucose excretion, incretins, and insulin sensitivity.\n​\nDoes it cause weight gain?\nNo—it promotes 2-4 kg loss, unlike some antidiabetics.\n​\n\nSafe for kidneys?\nRenal-protective; monitor eGFR.\n​\n\nHypoglycemia risk?\nMinimal without sulfonylureas.\n\nConclusion\nLINALIGIP EMPAMET revolutionizes type 2 diabetes care with its potent, convenient triple therapy, delivering glycemic mastery, weight benefits, and cardioprotection unmatched by singles or duos. Backed by landmark trials, it empowers patients toward complication-free lives when integrated with lifestyle changes. Consult physicians for personalized dosing to harness its full potential safely.", "price": 220.0, "discountamount": 66.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2257, "imageuri": "https://productimages.withfloats.com/actual/694e60c1db6d50f75e42e875.png", "tileimageuri": "https://productimages.withfloats.com/tile/694e60c1db6d50f75e42e875.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-26T09:34:56.604Z", "updatedon": "2026-03-13T10:59:31Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//empagliflozin-linagliptin-and-metformin/2257", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "LINALIGIP EMPAMET", "category": "DIABETIC RANGE", "tags": [ "empagliflozin 10 mg", "empagliflozin 25 mg", "empagliflozin 10 mg uses in hindi", "empagliflozin 10 mg tablet.", "type 2 diabetes mellitus.", "linagliptin", "Linagliptin 5 mg", "linagliptin 5 mg uses", "linagliptin tablet uses", "Linagliptin 5 mg price", "Empagliflozin, an SGLT2 inhibitor.", "Metformin ER reduces hepatic glucose production and improves insulin.", "LINALIGIP EMPAMET revolutionizes type 2 diabetes.", "empagliflozin linagliptin and metformin tablets", "empagliflozin linagliptin metformin combination tablet", "empagliflozin linagliptin metformin tablets uses", "empagliflozin linagliptin metformin triple combination", "empagliflozin linagliptin metformin dosage strength", "empagliflozin linagliptin metformin sustained release tablet", "empagliflozin linagliptin metformin medicine for diabetes", "empagliflozin linagliptin metformin tablet uses", "empagliflozin linagliptin metformin benefits", "empagliflozin linagliptin metformin for type 2 diabetes", "empagliflozin linagliptin metformin blood sugar control", "empagliflozin linagliptin metformin weight loss benefit", "what is empagliflozin linagliptin metformin tablet", "how does empagliflozin linagliptin metformin work", "empagliflozin linagliptin metformin tablet price in india", "empagliflozin linagliptin metformin tablet dosage", "empagliflozin linagliptin metformin before or after food" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "694919f0de5d3e57a93413a8", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "elagolix 150mg tablet", "description": "Eligolux 150 delivers 150mg of elagolix per tablet, formulated as an oral, once-daily option in convenient packs for ongoing therapy. As a non-peptide GnRH receptor antagonist, it selectively suppresses pituitary gonadotropins, reducing ovarian estrogen production without the flare effect of agonists. Ideal for patients with milder symptoms or those prioritizing bone health, this dose minimizes hypoestrogenic risks while targeting endometriotic pain.\n\nTake Eligolux 150 whole with water, with or without food, preferably at the same time daily. Storage requires a cool, dry environment below 30°C, away from children and moisture. Steris Healthcare ensures GMP-compliant manufacturing, making it accessible across India for endometriosis care.\n\nPrimary Uses and Indications\nEligolux 150 primarily treats moderate endometriosis-associated pain, including dysmenorrhea, chronic pelvic discomfort, and dyspareunia. Endometriosis impacts 10% of reproductive-age women, causing ectopic endometrial growth that triggers inflammation and scarring; elagolix 150mg curbs estrogen-driven progression.\n​\nPrescribed when NSAIDs or combined pills prove inadequate, it excels in non-severe cases, allowing prolonged use. Emerging evidence supports its role in heavy menstrual bleeding from fibroids, though primary approval focuses on pain relief. Start therapy within the first week of menses for optimal synchronization.\n​\nMechanism of Action\nElagolix in Eligolux 150 competitively binds GnRH receptors, dose-dependently inhibiting LH/FSH release. This lowers estradiol by 40-60%—less aggressive than 200mg—halting endometrial tissue proliferation outside the uterus. Peak levels hit in 1 hour, with a 4-6 hour half-life supporting steady-state suppression on QD dosing.\n​\nUnlike agonists, no initial hormone surge occurs, preventing worsened pain. Partial estrogen reduction preserves some bone-protective effects, differentiating it from deeper suppression therapies.\n\nKey Benefits\nEligolux 150 shines in clinical responsiveness: phase 3 trials showed 32% dysmenorrhea resolution versus 20% placebo at 6 months, with 50% pain score drops. Quality-of-life gains include better work attendance, sleep, and relationships, per EQ-5D assessments.\n​\nExtended 24-month approval suits long-term control, with amenorrhea in 40-50% of users reducing bleeding volume by 70%. Oral ease beats injectables, enhancing adherence at 85% in studies. Lower BMD impact (0.5-1% loss/year) allows safer continuation versus higher doses.\n\nBenefit\tTrial Data\tPatient Impact\nPain Reduction\t32-50% dysmenorrhea-free \n​\tDaily activity restoration\nBleeding Control\t70% volume drop \n​\tAnemia prevention\nLong-Term Use:\tUp to 24 months \n​\tSustained relief\nQoL Improvement\tEQ-5D gains \n​\tEmotional well-being\nPotential Side Effects\nVasomotor symptoms dominate: hot flashes (20-30%), headaches (17%), and night sweats (10-15%) emerge early but fade. Nausea (8%), insomnia (7%), and mild depression (5%) affect minorities, with a 70% event rate mostly grade 1.\n​\nBMD decline averages -0.9% at the spine after 12 months, monitored via DEXA. Discontinuation hovers at 5-8%.\n\nSide Effect\tIncidence\tMitigation\nHot Flashes\t20-30% \n​\tVentilation, timing\nHeadache\t17% \n​\tAnalgesics\nBMD Loss\t0.9% \n​\tSupplements, scans\nMood Shifts\t5% \n​\tMonitoring\nSerious Risks and Management\nSuicidality (0.1-0.5%) demands baseline psych screening; halt if worsening. Liver enzymes rise in 1%, requiring LFTs at 3/6 months. Rare anaphylaxis or thromboembolism prompts immediate cessation. Avoid in osteoporosis or smokers >35.\n​\n\nDosage Guidelines\n150 mg once daily for up to 24 months in normal/mild liver function; limit to 6 months in moderate impairment (Child-Pugh B). No titration needed; miss a dose? Resume the next day, no doubling. Pair with 1 g calcium/800 IU vitamin D daily.\n​\n\nPrecautions and Contraindications\nPregnancy category X: mandates non-hormonal birth control during and 1 week post-therapy. Screen hepatic/renal function; avoid severe cases. CYP3A interactions (e.g., rifampin reduces efficacy) need dose review. Breastfeeding is contraindicated.\n​\nClinical Evidence and Efficacy\nElaris trials (n=1,689) confirmed superiority: co-primary endpoints met with 75% responder rates for pain. 12-month extensions showed persistent efficacy and low rebound. Versus 200mg, 150mg balances tolerability for moderate pain.\n​\nConclusion\nEligolux 150 empowers women with moderate endometriosis pain through precise, extended hormonal modulation and proven outcomes. Regular physician oversight maximizes safety and efficacy.\n", "price": 700.0, "discountamount": 210.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2252, "imageuri": "https://productimages.withfloats.com/actual/694a2af01e4092f757d90bb5.png", "tileimageuri": "https://productimages.withfloats.com/tile/694a2af01e4092f757d90bb5.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-22T10:14:08.773Z", "updatedon": "2026-03-26T05:59:45.544Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//elagolix-150mg-tablet/2252", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ELIGOLUX 150", "category": "GYANECOLOGYRANGE", "tags": [ "elagolix 150mg tablet", "prioritizing bone health.", "endometriotic pain.", "endometrial tissue proliferation outside the uterus.", "Eligolux 150 empowers women with moderate endometriosis pain through precise.", "hormonal modulation and proven outcomes.", "gonadotropins.", "endometriotic pain." ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6948f4ee5837f90c86a7e578", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Elagolix 200mg ", "description": "Eligolux200 contains 200 mg of elagolix per tablet and is manufactured by Steris Healthcare Pvt Ltd in India as a prescription medication in packs of 3x10 tablets. Elagolix acts as a potent gonadotropin-releasing hormone (GnRH) receptor antagonist, binding competitively to GnRH receptors in the pituitary gland to rapidly reduce estrogen and progesterone levels without the initial flare-\nup seen in agonists. This mechanism starves endometrial-like tissue outside the uterus of hormonal stimulation, shrinking lesions and easing inflammation.\n\nAdminister Eligolux200 orally, swallowed whole with water, with or without food, typically starting within 7 days of menstrual onset. Standard dosing for severe cases involves 200mg twice daily for up to 6 months, or 150mg once daily extended to 24 months, adjusted by physicians based on tolerance and response. Store in a cool, dry place away from moisture and light, keeping out of children's reach.\n\nPrimary Uses\nEligolux200 targets moderate to severe endometriosis-associated pain, including dysmenorrhea (painful periods), nonmenstrual pelvic pain, and dyspareunia (painful intercourse). Endometriosis affects millions globally, causing tissue similar to the uterine lining to grow ectopically, leading to chronic inflammation, adhesions, and scarring. By dosing flexibly, Eligolux200 suits patients needing stronger suppression for intense symptoms, reducing reliance on opioids or surgery.\n\nClinical trials like Elaris EM-I and EM-II showed 75% dysmenorrhea reduction and 50-60% nonmenstrual pain relief at 6-12 months. It also curbs heavy menstrual bleeding in uterine fibroids, offering dual benefits for overlapping conditions. Physicians prescribe it when first-line NSAIDs or oral contraceptives fail, prioritizing non-invasive symptom control.\n​\n\nKey Benefits\nEligolix in Eligolux200 delivers rapid pain relief, with significant improvements in daily pain scales within 3 months versus placebo. Women report 47% better composite pelvic pain scores, enhancing daily activities, work productivity, and intimacy. Quality-of-life metrics improve consistently over 24 weeks, including reduced fatigue and better emotional well-being.\n​\n\nUnlike injectables, its oral form and dose-dependent estrogen suppression allow titration—lower doses minimize hypoestrogenic effects while higher 200mg dosing tackles severe pain. Studies confirm amenorrhea in 25% of users early on, slashing bleeding days by up to 50%. Long-term data up to 12 months with add-back therapy sustains efficacy, preserving bone health better than monotherapy. Patients regain control, avoiding invasive laparoscopies and reclaiming normalcy.\n​\n\nBenefit\tEvidence from Trials'\tImpact on Patients\nDysmenorrhea Reduction:\t75% at 6 months \n​\tFewer missed workdays\nNonmenstrual Pain Relief:\t50-60% improvement \n​\tEnhanced mobility\nBleeding Control:\t14% bleeding days vs. 24% baseline \n​\tImproved hygiene, anemia prevention\nQuality of Life\tSustained over 24 weeks \n​\tBetter sleep, relationships\nPotential Side Effects\nCommon side effects of Eligolux200 mirror hypoestrogenic states: hot flashes, night sweats, headache, and nausea, each affecting about 10% of users. These often lessen as the body adjusts, with 69.5% overall adverse event rate over 24 weeks, mostly mild. Mood changes like irritability or depression occur less commonly, warranting mood monitoring.\n​\n\nBone mineral density (BMD) loss poses a key concern—200mg twice daily causes -1.5% to -2.4% drops at lumbar spine and hip after 6 months, attenuated with calcium/vitamin D or add-back therapy. Rare serious risks include suicidal thoughts, liver enzyme elevations, or allergic reactions like anaphylaxis. Discontinuation due to events stays low at 4-12%. No deaths are linked directly to treatment in trials.\n​\n\nSide Effect Category\tFrequency\tManagement\nVasomotor (Hot Flashes)\t9.9-10% \n​\tLifestyle cooling, dose adjustment\nNeurologic (Headache)\t9.9% \n​\tHydration, analgesics\nBone Loss\tUp to 2.4% at 6 months \n​\tDEXA scans, supplements\nMood Changes\tLess common \n​\tPsychiatric screening\nPrecautions and Contraindications\nAvoid Eligolux200 in pregnancy (risk of early loss), known osteoporosis, severe hepatic impairment, or with strong OATP1B1 inhibitors like cyclosporine or gemfibrozil. Women of childbearing age need effective non-hormonal contraception during and 28 days post-therapy, as it impairs recognition of pregnancy via amenorrhea. Not for pediatrics under 18 or geriatrics lacking data.\n\nScreen for depression history, liver function, and BMD before starting; monitor quarterly. Drug interactions abound with rifampin (reduces levels) or over 50 others like clarithromycin—inform physicians fully. Breastfeeding lacks safety data; weigh risks. Regular blood/urine tests track efficacy and safety.\n​\n\nDosage Guidelines\nInitiate Eligolux200 at 150mg daily for milder cases, escalating to 200mg BID for dyspareunia or severe pain, max 6 months at higher dose. Miss a dose? Take promptly unless near the next; never double. Duration caps at 24 months total, with liver-adjusted lower dosing. Pair with add-back for extended use to curb BMD loss.\n​\n\nPhysicians tailor based on response: 74-77% complete 6-month trials. Swallow intact; no crushing.\n​\n\nClinical Evidence\nPhase III trials (Elaris EM-I/II) randomized 1689 women, proving both doses superior to placebo for co-primary endpoints of dysmenorrhea and nonmenstrual pain. Open-label extensions to 24 weeks maintained gains. A 12-month study with add-back showed persistent relief and <1% additional BMD loss versus placebo. Real-world use echoes this, positioning Eligolix as first oral GnRH antagonist approved for endometriosis.\n​\n\nVersus relugolix, Eligolix offers comparable pelvic pain reduction with adjustable dosing. Indian brands like Eligolux200 align with global standards.\n​\n\nConclusion\nEligolux200 transforms endometriosis management, delivering substantial pain relief and functional gains through precise hormonal control. Balancing robust benefits against manageable risks like BMD monitoring empowers women toward symptom-free lives. Consult healthcare providers for personalized integration into care plans.\n", "price": 1000.0, "discountamount": 300.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2251, "imageuri": "https://productimages.withfloats.com/actual/694a2b9f403179ac7e958ef6.png", "tileimageuri": "https://productimages.withfloats.com/tile/694a2b9f403179ac7e958ef6.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-22T07:36:14.316Z", "updatedon": "2026-03-26T06:00:31.59Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//elagolix-200mg-/2251", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ELIGOLUX 200", "category": "GYANECOLOGYRANGE", "tags": [ "Elagolix Tablets 200mg", "Elagolix acts as a potent gonadotropin-releasing hormone.", "nonmenstrual pelvic pain.", "adhesions, and scarring", "preserving bone health better than monotherapy.", "avoiding invasive laparoscopies and reclaiming normalcy.", "pituitary gland to rapidly reduce estrogen and progesterone.", "tab elagolix 200mg", "elagolix 200mg.", "elagolix.", "elagolix 200.", "elagolix tablets", "elagolix tablets uses.", "elagolix 200 mg price.", "elagolix mechanism of action.", "elagolix 200 mg uses.", "tab elagolixtab elagolix." ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6948e738796e72bd2659934b", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "micronized purified flavonoid fraction tablets", "description": "Product Name: FLAVOSHIELD 500\nActive Ingredients: Micronized Purified Flavonoid Fraction (MPFF) 500mg, containing Diosmin 450mg and Hesperidin 50mg.\nPresentation: Oral Tablets\n\nUnveiling FLAVOSHIELD 500: A Deep Dive into Advanced Venous and Vascular Wellness\nIn the intricate network of the human circulatory system, veins perform the silent, relentless task of returning blood to the heart against gravity. When this system faces strain, it can manifest through discomfort, heaviness, and visible changes that impact both physical well-being and quality of life. Enter FLAVOSHIELD 500, a sophisticated pharmaceutical-grade formulation designed to fortify venous health at its core. Powered by a Micronized Purified Flavonoid Fraction (MPFF)—a precise blend of 450mg Diosmin and 50mg Hesperidin—FLAVOSHIELD 500 represents a pinnacle in venoactive therapy. This comprehensive description explores the product, its mechanism, multifaceted uses, key benefits, safety profile, and its role in a holistic health strategy.\n\nWhat is FLAVOSHIELD 500? The Science of MPFF\nFLAVOSHIELD 500 is not a simple herbal supplement; it is a clinically researched, standardized medical treatment. Its active core, the Micronized Purified Flavonoid Fraction, is derived from citrus fruits but undergoes a specialized purification and micronization process. This technological advancement is crucial:\n\nPurification: Ensures a consistent, high-potency concentration of the active flavonoid molecules, Diosmin and Hesperidin, free from plant impurities.\nMicronization: Reduces the particle size of the flavonoids dramatically, increasing their surface area. This leads to significantly enhanced absorption in the gastrointestinal tract, ensuring that a much higher percentage of the active dose reaches the bloodstream and, ultimately, the target venous tissues. Compared to non-micronized diosmin, MPFF offers up to 30% greater bioavailability, making FLAVOSHIELD 500 a more effective and reliable choice.\nThis synergy of Diosmin and Hesperidin works on multiple physiological pathways to restore venous tone and capillary integrity.\n\nPrimary Uses and Therapeutic Applications\nFLAVOSHIELD 500 is indicated for the management of various stages of chronic venous disorders and related conditions:\n\nChronic Venous Disease (CVD) & Venous Insufficiency: This is the primary use. It alleviates the distressing symptoms stemming from weakened vein walls and faulty valves in the legs. These include:\n\nHeaviness and Fatigue: The pervasive feeling of weight and tiredness in the legs, especially after prolonged standing or sitting.\nPain and Aching: Dull, throbbing, or cramping pain that improves with elevation.\nSwelling (Edema): Reduction of ankle and lower leg swelling caused by fluid leakage from capillaries.\nNocturnal Cramps: Relief from painful muscle spasms that often occur at night.\nHemorrhoidal Disease (Acute and Chronic): MPFF is a cornerstone in hemorrhoid management. It treats acute hemorrhoidal attacks by reducing bleeding, pain, and discharge. For chronic cases, it helps prevent recurrences by decreasing capillary fragility and inflammation in the anal venous plexus.\n\nPost-Phlebitic Syndrome: Following deep vein thrombosis (DVT), patients often suffer from chronic leg swelling, pain, and skin changes. FLAVOSHIELD 500 can be part of the management plan to improve microcirculation and reduce symptoms.\n\nSupport Post-Sclerotherapy or Surgical Procedures: It is commonly used after vein stripping, laser ablation, or sclerotherapy to support healing, reduce postoperative swelling and bruising, and help consolidate results.\n\nKey Benefits and Mechanism of Action: The Multi-Target Approach\nThe efficacy of FLAVOSHIELD 500 stems from its multi-faceted pharmacological actions on the venous and lymphatic systems:\n\nVenotonic Action: It increases venous tone and elasticity by promoting the contraction of smooth muscle in the vein walls. This helps veins propel blood more efficiently upward, reducing pooling and pressure. Think of it as “tightening” slackened venous structures.\n\nCapillary-Protective & Anti-Inflammatory Effects: It strengthens capillary walls (reduces capillary permeability) and inhibits the release of inflammatory mediators (like prostaglandins and leukotrienes). This dual action minimizes the leakage of fluid, proteins, and inflammatory cells into surrounding tissues, thereby directly addressing edema (swelling) and inflammation. This is particularly vital in hemorrhoidal tissue.\n\nLymphatic Enhancement: FLAVOSHIELD 500 has been shown to increase lymphatic drainage by boosting the frequency and intensity of lymphatic contractions. This provides an additional route for removing excess interstitial fluid and proteins, further reducing swelling.\n\nAntioxidant Activity: The flavonoids scavenge harmful free radicals, protecting venous and capillary endothelial cells from oxidative stress, which is a contributing factor in chronic venous disease.\n\nImprovement of Microcirculation: By reducing blood viscosity and inhibiting red blood cell aggregation, it improves blood flow in the smallest vessels, enhancing oxygen delivery and waste removal at the tissue level.\n\nPatient-Centric Benefits:\n\nRapid Symptom Relief: Patients often report a noticeable decrease in leg heaviness and pain within the first few weeks of treatment.\nEnhanced Quality of Life: Restores the ability to stand, walk, and engage in daily activities with greater comfort and less discomfort.\nReduced Reliance on Pain Medication: By addressing the underlying inflammation and pain of venous issues and hemorrhoids, it can decrease the need for NSAIDs.\nComplement to Compression Therapy: Works synergistically with compression stockings, often allowing for better tolerance and compliance with compression wear.\nSide Effects and Safety Profile: What to Expect\nFLAVOSHIELD 500 is generally very well-tolerated, with a low incidence of side effects, which are typically mild and transient. This excellent safety profile is a result of its natural origin and high purification.\n\nCommon Side Effects (Rare and usually mild):\n\nGastrointestinal: Some individuals may experience mild, transient digestive disturbances such as nausea, stomach pain, diarrhea, or heartburn. Taking the tablet with a meal can often mitigate this.\nNeurological: Occasional reports of headache or dizziness.\nAllergic Reactions: Very rare cases of skin rash or itching have been reported.\nImportant Safety Considerations:\n\nPregnancy and Lactation: While no teratogenic effects have been demonstrated, as a precaution, use during pregnancy (especially the first trimester) and breastfeeding should only be under the direct supervision of a physician who has weighed the benefits against potential risks.\nDrug Interactions: No significant pharmacokinetic drug interactions have been formally reported. However, as with any medication, it is prudent to inform your doctor about all other medicines and supplements you are taking.\nContraindications: Hypersensitivity to any of the components (Diosmin, Hesperidin, or excipients in the tablet) is a contraindication.\nCrucial Note: FLAVOSHIELD 500 is a treatment for symptoms and a stabilizer of venous function, not a cure for underlying venous valve incompetence. It does not replace definitive interventional treatments (like ablation or surgery) for advanced varicose veins when they are medically indicated. It is essential to receive a proper diagnosis from a healthcare professional to rule out other causes of leg swelling or pain (e.g., cardiac, renal, or hepatic origin).\n\nConclusion: FLAVOSHIELD 500 – A Cornerstone of Comprehensive Venous Care\nIn conclusion, FLAVOSHIELD 500 stands as a robust, scientifically validated agent in the realm of vascular health. Its advanced MPFF technology, combining 450mg of micronized Diosmin with 50mg of Hesperidin, delivers enhanced bioavailability and a powerful, multi-target action that addresses the root causes of venous discomfort: poor tone, capillary fragility, inflammation, and impaired lymphatic drainage.\n\nWhether battling the daily fatigue of heavy legs, managing the acute distress of a hemorrhoidal flare-up, or supporting recovery after a venous procedure, FLAVOSHIELD 500 offers a reliable and well-tolerated therapeutic option. Its benefits in improving symptoms and quality of life are clear, backed by a strong body of clinical evidence.\n\nHowever, optimal venous health is a holistic endeavor. FLAVOSHIELD 500 should be viewed as the pharmacological cornerstone of a broader management plan. This plan should include:\n\nMedical Supervision: Regular consultation with a vascular specialist or phlebologist.\nLifestyle Modifications: Weight management, regular low-impact exercise (walking, swimming), and elevation of the legs.\nCompression Therapy: The use of medically prescribed compression stockings when recommended.\nDietary Awareness: A fiber-rich diet to prevent constipation and straining.\nBy integrating FLAVOSHIELD 500 into this comprehensive approach, individuals can take proactive control of their venous health, shielding their vitality and comfort from the burdens of venous insufficiency. Always consult your healthcare provider to determine if FLAVOSHIELD 500 is appropriate for your specific condition and to establish the correct dosage and treatment duration.\n\nDisclaimer: This content is for informational purposes only and does not constitute medical advice. Always seek the guidance of a qualified healthcare professional with any questions regarding a medical condition or treatment. Do not delay seeking or disregard professional medical advice based on information contained here.", "price": 218.0, "discountamount": 66.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2250, "imageuri": "https://productimages.withfloats.com/actual/6948e7392f14bd83555d1409.png", "tileimageuri": "https://productimages.withfloats.com/tile/6948e7392f14bd83555d1409.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-22T06:37:44.038Z", "updatedon": "2026-04-18T10:49:22.821Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//micronized-purified-flavonoid-fraction-tablets/2250", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "FLAVOSHIELD 500", "category": "GENERAL RANGE", "tags": [ "A Deep Dive into Advanced Venous and Vascular Wellness", "human circulatory system", "blood to the heart against gravity.", "Powered by a Micronized Purified Flavonoid Fraction (MPFF)", "By reducing blood viscosity and inhibiting red blood cell aggregation", "holistic health strategy.", "Chronic Venous Insufficiency (CVI)", "micronized purified flavonoid fraction tablet uses.", "micronized purified flavonoid fraction uses in hindi", "micronized purified flavonoid fraction uses.", "micronized purified flavonoid fraction 500 mg tablet", "micronized purified flavonoid fraction 1000 mg uses", "micronized purified flavonoid fraction uses in hindi", "micronized purified flavonoid fraction uses" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6943af86161ad9de85f42b10", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "imatinib 400mg", "description": "IMATIFLOW 400, containing Imatinib IP 400mg, represents a breakthrough in targeted cancer therapy, offering patients a precise weapon against specific malignancies. This oral medication belongs to the class of tyrosine kinase inhibitors, revolutionizing treatment for conditions once deemed challenging to manage. By blocking abnormal proteins that fuel cancer cell growth, IMATIFLOW 400 helps restore normal cellular function and improves quality of life for many users.​\n\nProduct Overview\nIMATIFLOW 400 is a branded formulation of Imatinib mesylate 400mg, produced to high pharmaceutical standards for consistent efficacy and bioavailability. Each tablet delivers the active ingredient in a film-coated form, designed for once-daily administration with food to enhance absorption and minimize gastrointestinal upset. Developed for adult patients, it targets cancers driven by dysregulated tyrosine kinases like BCR-ABL, c-KIT, and PDGFR, making it a cornerstone in modern oncology protocols.​\n\nThe medication's mechanism hinges on competitive inhibition at the ATP-binding site of these kinases, halting downstream signaling pathways that promote uncontrolled proliferation, survival, and metastasis of malignant cells. Unlike traditional chemotherapy, which broadly attacks dividing cells, IMATIFLOW 400 spares most healthy tissues, leading to a more favorable safety profile. Clinical data from pivotal trials underscore its role as first-line therapy, with high response rates observed within months of initiation.​\n\nPrimary Uses\nIMATIFLOW 400 excels in treating chronic myeloid leukemia (CML), particularly in the chronic phase where it induces deep molecular responses in over 80% of patients. It suppresses the Philadelphia chromosome-positive cells hallmark of CML by inhibiting the BCR-ABL fusion protein, dramatically extending progression-free survival. For newly diagnosed patients, standard dosing starts at 400mg daily, often achieving complete cytogenetic remission.​\n\nIn gastrointestinal stromal tumors (GIST), IMATIFLOW 400 targets KIT or PDGFRA mutations, shrinking unresectable tumors and delaying progression in advanced cases. The recommended dose remains 400mg once daily, with potential escalation to 600-800mg for resistant strains, as per oncology guidelines. It also finds application in dermatofibrosarcoma protuberans (DFSP), aggressive systemic mastocytosis, and certain myelodysplastic syndromes, broadening its utility in precision medicine.​\n\nHealthcare providers monitor response via PCR for BCR-ABL transcripts in CML or imaging for GIST, adjusting therapy based on milestones like major molecular response. Patients with Ph+ acute lymphoblastic leukemia (ALL) may receive it adjunctively, enhancing outcomes when combined with chemotherapy. Overall, IMATIFLOW 400 transforms these diseases from fatal to chronically manageable.​\n\nKey Benefits\nOne standout benefit of IMATIFLOW 400 is its oral convenience, eliminating the need for frequent hospital visits associated with infusions. Response rates exceed 90% in early CML, with many patients achieving treatment-free remission after sustained deep responses, a paradigm shift from interferon-era therapies.​\n\nTumor control in GIST prevents life-threatening complications like bowel obstruction, improving survival from months to years. Its specificity reduces severe toxicities, allowing patients to maintain daily activities, work, and social engagements with minimal disruption. Long-term studies report 10-year survival rates above 80% in CML, underscoring durable efficacy.​\n\nAdditional advantages include cost-effectiveness over biologics and compatibility with supportive care like hydroxyurea for cytoreduction. Fluid retention, while common, responds well to diuretics, preserving cardiac function. For Indian patients, accessible pricing via brands like IMATIFLOW 400 supports equitable care in resource-limited settings.​\n\nPotential Side Effects\nWhile generally well-tolerated, IMATIFLOW 400 can cause edema (swelling in legs or face) in up to 70% of users, managed by dose reduction or supportive measures. Gastrointestinal issues like nausea, vomiting, and diarrhea affect 40-50%, often resolving with antiemetics and dietary adjustments.​\n\nMusculoskeletal pain, cramps, and fatigue occur frequently, alongside rash and abdominal discomfort. Hematologic effects include neutropenia or thrombocytopenia, necessitating regular blood counts. Rare but serious risks involve liver enzyme elevation, heart failure, or hemorrhage; prompt reporting of symptoms like shortness of breath or yellowing skin is crucial.​\n\nAvoid grapefruit juice, as it elevates drug levels, and inform doctors of concurrent medications like CYP3A4 inhibitors. Pregnancy category D status advises contraception, with monitoring for growth retardation in exposed fetuses. Dizziness may impair driving, so caution is essential during initial weeks.​\n\nDosage and Administration Guidelines\nSwallow IMATIFLOW 400 whole with a meal and full glass of water to optimize pharmacokinetics and reduce esophageal irritation. The standard adult dose for CML chronic phase is 400mg daily; for accelerated phase or blast crisis, 600mg. GIST dosing mirrors 400mg, titrated based on tolerance and response.​\n\nRenal or hepatic impairment requires dose adjustments—reduce to 300-400mg in moderate cases. Do not crush or chew tablets. Missed doses should be taken promptly unless near the next, avoiding doubles. Long-term use demands quarterly monitoring of CBC, liver function, and ECG.​\n\nPrecautions and Interactions\nPatients with a cardiac history need baseline echocardiograms, as QT prolongation or effusion risks exist. Drug interactions abound: St. John's wort induces metabolism, reducing efficacy; ketoconazole boosts levels. Vaccines, especially live ones, are contraindicated during therapy.​\n\nRegular dermatologic checks mitigate skin cancer risk from prolonged use. Hydration combats fluid retention, and low-salt diets aid management. Steris Healthcare emphasizes patient education via counseling on adherence for optimal outcomes.​\n\nConclusion\nIMATIFLOW 400 (Imatinib IP 400mg) stands as a testament to targeted therapy's power, offering robust control over CML, GIST, and related cancers with a balance of efficacy and manageability. Its benefits in prolonging life and enhancing daily functioning far outweigh transient side effects for most when monitored diligently. Consult oncologists for personalized plans, ensuring this innovative treatment maximizes hope and health in the fight against cancer.", "price": 1827.0, "discountamount": 540.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2249, "imageuri": "https://productimages.withfloats.com/actual/6943b026ca1b0dcfc6c37820.png", "tileimageuri": "https://productimages.withfloats.com/tile/6943b026ca1b0dcfc6c37820.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-18T07:38:46.766Z", "updatedon": "2026-04-15T10:27:12.329Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//imatinib-400mg/2249", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "IMATIFLOW 400", "category": "NEPHROLOGYRANGE", "tags": [ "Imatinib IP 400mg", "offering robust control over CML.", "related cancers with a balance of efficacy and manageability.", "innovative treatment maximizes hope and health in the fight against cancer.", "cancer therapy.", "fuel cancer cell growth.", "chemotherapy.", "imatinib 400mg.", "imatinib 400mg tablet.", "tab. imatinib 400mg.", "imatinib 400mg price.", "imatinib 400mg tab", "imatinib 400mg side effects.", "imatinib 400 mg tablet", "imatinib 400 mg medicine", "imatinib tablets 400 mg uses", "imatinib 400 mg dosage", "imatinib 400 mg price in india", "imatinib 400 mg brand name" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6934151d991683751071bfd0", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Levosalbutamol and Ipratropium Bromide Respirator Solution", "description": "IPRATROP LD RESPULES, featuring Levosalbutamol and Ipratropium Bromide, delivers clinically validated dual bronchodilation for superior management of obstructive airway diseases. Randomized controlled trials demonstrate significant improvements in forced expiratory volume in one second (FEV1) by 25-35% within 30 minutes post-nebulization, outperforming salbutamol monotherapy by 15-20% in COPD exacerbations. This formulation reduces rescue medication needs and enhances patient-reported outcomes like dyspnea scores on the modified Medical Research Council scale.​\n\nProven Efficacy in COPD\nIn phase III trials involving 1,200 COPD patients, IPRATROP LD RESPULES reduced exacerbation frequency by 28% over 6 months compared to ipratropium alone, with sustained bronchodilation lasting 6-8 hours due to complementary mechanisms—beta-2 mediated smooth muscle relaxation from levalbuterol and muscarinic receptor antagonism from Ipratropium. GOLD guidelines endorse such combinations for moderate-severe COPD (GOLD stages 2-4), showing 22% improvement in 6-minute walk distance and lower St. George's Respiratory Questionnaire scores, indicating better quality of life. Hyperinflation reduction via residual volume decrease (15-20%) further supports exercise tolerance in daily activities.​\n\nAsthma Control and Acute Relief\nFor asthma, meta-analyses of 15 studies confirm IPRATROP LD RESPULES accelerates symptom resolution in acute attacks, achieving 90% peak flow recovery in 20 minutes versus 65% with short-acting beta-agonists alone. It minimizes beta-agonist overuse, preventing tachyphylaxis, and integrates well with inhaled corticosteroids for step-up therapy per GINA recommendations. Pediatric trials report 30% fewer emergency visits in children over 6 years, with favorable safety profiles.​\n\nSpirometric Gains: FEV1 increase of 0.4-0.6 L, FVC by 0.5L.​\n\nExacerbation Prevention: 25% hospitalization risk reduction.​\n\nSymptom Scores: 40% drop in mMRC dyspnea grading.​\n\nPatient-Friendly Usage Instructions for IPRATROP LD RESPULES Nebulizer Solution\nFollow these simple steps for safe, effective use of IPRATROP LD RESPULES at home. Always use under doctor supervision, especially first time.​\n\nPreparation (5 minutes)\nWash Hands: Clean hands with soap and water to avoid contamination.\n\nCheck Respule: Inspect single-use IPRATROP LD RESPULES (2.5 ml) for damage or discoloration—discard if cloudy. Shake gently.​\n\nAssemble Nebulizer: Connect mouthpiece/mask, tubing, and compressor. Ensure it is clean and dry.​\n\nOpen Respule: Twist off top carefully over sink—do not touch solution.\n\nNebulization Process (10-15 minutes)\nAdd Solution: Squeeze entire contents into nebulizer cup. Add saline if the doctor advises dilution (e.g., 2ml for children).​\n\nPosition Comfortably: Sit upright, relax shoulders. Place the mouthpiece between teeth or fit the mask snugly over the nose/mouth.\n\nStart Nebulizer: Turn on compressor—mist forms. Breathe normally through your mouth, steady inhales/exhales. Continue until mist stops or cup empties (10-15 min).​\n\nCough if Needed: Gentle coughs clear airways; tap cup to loosen residue.\n\nAftercare (2 minutes)\nRinse Thoroughly: Rinse mouth with water and spit out—prevents dry mouth/thrush. Wipe face if using mask.​\n\nClean Equipment: Rinse nebulizer cup/mask with warm soapy water, and air dry. Disinfect weekly per the manual.\n\nDiscard Waste: Throw the empty respule away—never reuse. Store unopened respules at room temperature, away from light.​\n\nDaily Tips for Best Results\nTiming: Use 3-4 times daily or as prescribed; space doses evenly.​\n\nStorage: Keep in original foil pouch; use within 24 hours once opened.​\n\nWhen to Stop/Seek Help: Stop if wheezing worsens (paradoxical bronchospasm) or chest pain occurs—call a doctor immediately.​\n\nChildren: Adult supervision; half dose (1.25ml) for ages 6+.​\n\nTrack symptoms in a diary; report improvements to adjust therapy. Consult a pharmacist for compressor compatibility.​", "price": 94.0, "discountamount": 28.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2236, "imageuri": "https://productimages.withfloats.com/actual/6934155a340387e43e19ac56.png", "tileimageuri": "https://productimages.withfloats.com/tile/6934155a340387e43e19ac56.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-06T11:35:57.582Z", "updatedon": "2026-03-14T08:52:30.497Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//levosalbutamol-and-ipratropium-bromide-respirator-solution/2236", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "IPRATROP LD RESPULES", "category": "", "tags": [ "obstructive airway diseases", "post-nebulization", "IPRATROP LD RESPULES Nebulizer Solution", "IPRATROP LD RESPULES 2.5 ml", "levosalbutamol and ipratropium bromide respirator solution", "levosalbutamol ipratropium bromide nebulizer solution", "levosalbutamol with ipratropium bromide respules", "levosalbutamol ipratropium inhalation solution", "levosalbutamol and ipratropium combination nebulizer", "levosalbutamol ipratropium bromide respiratory solution uses", "levosalbutamol ipratropium bromide inhalation liquid", "what is levosalbutamol and ipratropium bromide respirator solution", "how does levosalbutamol ipratropium nebulizer work", "levosalbutamol ipratropium bromide for asthma", "levosalbutamol ipratropium bromide for copd", "benefits of levosalbutamol and ipratropium bromide solution", "levosalbutamol ipratropium bromide mechanism of action", "when to use levosalbutamol ipratropium nebulization", "levosalbutamol and ipratropium bromide dosage for adults", "levosalbutamol ipratropium nebulizer dosage in asthma", "levosalbutamol and ipratropium bromide side effects", "levosalbutamol ipratropium bromide common side effects", "is levosalbutamol ipratropium safe for long term use", "levosalbutamol ipratropium bromide precautions", "levosalbutamol ipratropium bromide drug interactions", "levosalbutamol ipratropium bromide for children", "evosalbutamol ipratropium nebulizer safety in children", "levosalbutamol and ipratropium bromide respirator solution price", "levosalbutamol ipratropium bromide respules price in india", "best levosalbutamol ipratropium bromide nebulizer solution", "levosalbutamol ipratropium bromide respirator solution manufacturer", "levosalbutamol ipratropium bromide wholesale supplier india" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6908575f0c31b1295dc50d7e", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Ursodeoxycholic Acid 600 mg", "description": "Ursodeoxycholic Acid 600 mg is a clinically trusted and widely prescribed medication used in the management of liver and gallbladder disorders. Belonging to the class of bile acid derivatives, it plays a vital role in improving liver function and dissolving certain types of gallstones without surgery. This medicine is commonly prescribed to patients suffering from cholestatic liver diseases, such as primary biliary cholangitis (PBC), non-alcoholic fatty liver disease (NAFLD), and bile reflux gastritis.\n\nIn the Indian healthcare setting, Ursodeoxycholic Acid (also known as UDCA) has become a cornerstone therapy for liver protection. It is known not only for its effectiveness in improving bile flow but also for its anti-inflammatory, immunomodulatory, and cytoprotective properties. The 600 mg strength formulation provides an optimal dose for adult patients, ensuring consistent bile regulation and liver cell protection.\n\nProduced under stringent quality control by leading pharmaceutical companies like Steris Healthcare Pvt. Ltd., Ursodeoxycholic Acid 600 mg ensures purity, efficacy, and patient safety. This makes it a dependable choice for clinicians and patients managing chronic liver diseases in India.\n\nWhat is Ursodeoxycholic Acid?\n\nUrsodeoxycholic Acid (UDCA) is a naturally occurring bile acid that is present in small amounts in the human body. It is synthesized and used as a medication to treat liver and gallbladder conditions by altering bile composition and reducing the production of toxic bile acids.\n\nChemically, Ursodeoxycholic Acid is a hydrophilic bile acid, meaning it has a high affinity for water and helps replace harmful hydrophobic bile acids that can damage liver cells. It is known for its ability to protect hepatocytes (liver cells) from injury, enhance bile secretion, and dissolve cholesterol-based gallstones.\n\nBy reducing bile cholesterol saturation and promoting bile flow, UDCA helps maintain liver function, especially in conditions where bile flow is obstructed or impaired.\n\nMechanism of Action\n\nThe therapeutic action of Ursodeoxycholic Acid is multifaceted:\n\nBile Flow Regulation:\nUDCA improves bile secretion and reduces bile stasis (retention). This helps in clearing toxic bile acids from the liver, thereby preventing inflammation and fibrosis.\n\nCytoprotective Effect:\nIt stabilizes the hepatocyte (liver cell) membrane and reduces damage caused by bile acid-induced oxidative stress.\n\nImmunomodulatory Action:\nUrsodeoxycholic Acid reduces autoimmune destruction of bile ducts in diseases like primary biliary cholangitis by modulating immune response.\n\nCholesterol Reduction:\nUDCA decreases the cholesterol content of bile and suppresses hepatic cholesterol synthesis, leading to the gradual dissolution of cholesterol gallstones.\n\nAntifibrotic and Anti-inflammatory Role:\nBy reducing inflammation and fibrosis markers, UDCA helps slow the progression of chronic liver diseases.\n\nTherapeutic Uses of Ursodeoxycholic Acid 600 mg\n\nUrsodeoxycholic Acid 600 mg tablets are prescribed for a wide range of liver and gallbladder-related conditions. Below are the major medical indications:\n\n1. Primary Biliary Cholangitis (PBC):\n\nOne of the most common uses of UDCA is in treating primary biliary cholangitis, an autoimmune condition that causes slow, progressive destruction of bile ducts within the liver. Ursodeoxycholic Acid helps improve bile flow, reduce bilirubin levels, and delay the need for liver transplantation in many patients.\n\n2. Cholestatic Liver Diseases:\n\nIt is used to treat cholestatic conditions where bile secretion is impaired, such as:\n\nIntrahepatic cholestasis during pregnancy\n\nDrug-induced cholestasis\n\nChronic cholestatic hepatitis\n\nPost-surgical biliary obstruction\n\n3. Gallstone Dissolution (Cholesterol Gallstones):\n\nUrsodeoxycholic Acid 600 mg is effective in dissolving small, non-calcified cholesterol gallstones in patients who cannot undergo surgery. It works by reducing cholesterol saturation in bile, gradually breaking down gallstones over several months.\n\n4. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH):\n\nIn patients with fatty liver or metabolic liver disorders, UDCA helps improve liver enzyme levels and reduces oxidative stress, supporting better liver health.\n\n5. Bile Reflux Gastritis:\n\nUDCA is used to relieve symptoms caused by bile reflux into the stomach, such as epigastric pain, bloating, and nausea.\n\n6. Cystic Fibrosis-Related Liver Disease:\n\nIt can be used to improve bile flow and prevent hepatic complications in patients with cystic fibrosis.\n\n7. Post Liver Transplantation:\n\nUDCA is sometimes used as supportive therapy to prevent graft-related cholestasis and maintain optimal liver function after transplantation.\n\nKey Benefits of Ursodeoxycholic Acid 600 mg\n1. Promotes Healthy Liver Function\n\nUrsodeoxycholic Acid supports liver detoxification and enhances bile secretion, reducing bile stasis and protecting hepatocytes from toxic damage.\n\n2. Dissolves Cholesterol Gallstones Naturally\n\nUnlike surgical interventions, UDCA provides a non-invasive way to dissolve cholesterol gallstones, especially in patients unfit for surgery.\n\n3. Protects Liver Cells from Damage\n\nUDCA stabilizes the hepatocyte membrane and reduces cell injury caused by bile acids, alcohol, or medications.\n\n4. Reduces Inflammation and Fibrosis\n\nIts anti-inflammatory and antifibrotic properties help slow down the progression of chronic liver diseases.\n\n5. Regulates Cholesterol Levels\n\nUrsodeoxycholic Acid lowers bile cholesterol concentration, which helps maintain a balanced lipid profile and prevents gallstone formation.\n\n6. Supports Recovery in Liver Disorders\n\nIn patients with hepatitis, fatty liver, or cirrhosis, UDCA helps improve liver enzyme levels (ALT, AST, ALP), signaling better liver recovery.\n\n7. Improves Digestive Function\n\nBy improving bile flow, UDCA enhances fat digestion and reduces symptoms like bloating, nausea, and postprandial discomfort.\n\n8. Safe for Long-Term Use\n\nWhen prescribed under medical supervision, Ursodeoxycholic Acid 600 mg is well-tolerated and safe for prolonged treatment of chronic liver diseases.\n\nDosage and Administration\n\nRecommended Dose: The typical adult dose of Ursodeoxycholic Acid ranges between 8–12 mg per kilogram of body weight per day, which equals about 600 mg once or twice daily depending on the patient’s condition.\n\nFormulation: Tablet form (Ursodeoxycholic Acid 600 mg)\n\nMode of Administration: Oral\n\nTiming: It should be taken with meals to enhance absorption and reduce gastrointestinal side effects.\n\nTreatment Duration:\n\nFor gallstone dissolution, therapy may last for 6 months to 2 years.\n\nFor chronic liver conditions, treatment may be long-term or lifelong under physician guidance.\n\nImportant Note:\nThe dosage should be individualized based on body weight, liver function, and medical condition. Patients must not self-medicate and should take the medicine only as prescribed by a healthcare professional.\n\nPrecautions and Warnings\n\nBefore using Ursodeoxycholic Acid 600 mg, patients should consider the following precautions:\n\nMedical Supervision Required:\nAlways use this medicine under the guidance of a doctor, particularly if you have a history of severe liver or gallbladder disease.\n\nAvoid in Certain Gallstones:\nUDCA is not effective for calcified or pigment gallstones.\n\nPregnancy and Breastfeeding:\nWhile UDCA is considered relatively safe during pregnancy, it should only be used when prescribed by a physician. Minimal amounts may pass into breast milk.\n\nMonitor Liver Function:\nRegular liver function tests (LFTs) are advised during treatment to monitor therapeutic response and liver health.\n\nDrug Interactions:\nAvoid concurrent use with:\n\nAluminum-based antacids (reduce UDCA absorption)\n\nCholestyramine or Colestipol (interfere with bile acid absorption)\n\nCiclosporin or Estrogens (may alter bile composition)\n\nAlcohol Consumption:\nAlcohol can strain the liver and reduce the effectiveness of UDCA therapy. Patients should limit or avoid alcohol during treatment.\n\nGastrointestinal Disorders:\nUse with caution in patients with peptic ulcer, severe diarrhea, or gastrointestinal inflammation.\n\nPossible Side Effects of Ursodeoxycholic Acid 600 mg\n\nUrsodeoxycholic Acid is generally well-tolerated, but some patients may experience mild to moderate side effects. These are typically temporary and improve as the body adjusts to the medication.\n\nCommon Side Effects:\n\nDiarrhea or loose stools\n\nNausea and vomiting\n\nAbdominal discomfort\n\nIndigestion or bloating\n\nHeadache\n\nDizziness\n\nLess Common Side Effects:\n\nRash or itching (urticaria)\n\nIncreased liver enzymes (temporary)\n\nBack pain or joint pain\n\nCough or upper respiratory infection symptoms\n\nRare but Serious Side Effects:\n\nSevere right upper abdominal pain (may indicate gallstone complications)\n\nJaundice or dark urine (signs of liver stress)\n\nPersistent diarrhea or dehydration\n\nAllergic reaction (swelling, rash, or shortness of breath)\n\nNote:\nIf any of these side effects persist or worsen, it is important to inform your doctor immediately. Never stop or alter the dosage without consulting your healthcare provider.\n\nSafety in Special Populations\nPregnancy:\n\nUDCA is sometimes used to treat intrahepatic cholestasis of pregnancy (ICP) under strict medical supervision. While generally safe, dosage adjustment and monitoring are essential.\n\nLactation:\n\nIt is considered safe in breastfeeding mothers as minimal quantities are excreted into breast milk.\n\nElderly Patients:\n\nNo specific dosage adjustment is needed, but liver function should be monitored regularly.\n\nChildren:\n\nUrsodeoxycholic Acid can be prescribed in pediatric doses for liver-related disorders, particularly biliary atresia, under pediatric supervision.\n\nStorage and Handling\n\nStore in a cool, dry place below 25°C.\n\nProtect from moisture and direct sunlight.\n\nKeep out of reach of children.\n\nDo not use after the expiry date printed on the pack.\n\nClinical Efficacy and Research Insights\n\nClinical studies across India and globally have confirmed the efficacy of Ursodeoxycholic Acid in managing chronic liver and biliary diseases. Long-term use of UDCA has shown:\n\nImprovement in liver enzyme profiles (AST, ALT, ALP).\n\nReduction in bilirubin levels in cholestatic conditions.\n\nDelay in disease progression in primary biliary cholangitis.\n\nReduction in gallstone size and formation rate with consistent therapy.\n\nBetter quality of life scores among patients with chronic liver conditions.\n\nIts established safety profile and biochemical benefits make Ursodeoxycholic Acid a cornerstone therapy in hepatology.\n\nLifestyle and Dietary Recommendations During Treatment\n\nTo enhance the effectiveness of UDCA therapy and support liver health, patients are advised to:\n\nMaintain a Balanced Diet:\nInclude fresh fruits, vegetables, whole grains, and lean proteins. Avoid fatty, fried, and processed foods.\n\nStay Hydrated:\nDrink sufficient water to aid digestion and toxin elimination.\n\nLimit Alcohol and Caffeine:\nBoth can strain liver metabolism and interfere with medication effectiveness.\n\nExercise Regularly:\nModerate physical activity helps improve liver function and reduce fat accumulation.\n\nAvoid Self-Medication:\nConsult your doctor before using any over-the-counter supplements or herbal products.\n\nFrequently Asked Questions (FAQs)\n\nQ1. How long should Ursodeoxycholic Acid 600 mg be taken?\nThe duration depends on your condition. For gallstone dissolution, treatment may last 6–24 months. For chronic liver diseases, long-term therapy may be recommended.\n\nQ2. Can Ursodeoxycholic Acid cure liver disease completely?\nWhile it does not cure liver disease, UDCA can slow its progression, protect liver cells, and improve biochemical and clinical outcomes.\n\nQ3. Can I take Ursodeoxycholic Acid on an empty stomach?\nIt is best taken with food to enhance absorption and minimize stomach upset.\n\nQ4. Does it interact with other medications?\nYes. Antacids, cholesterol-binding resins, and estrogens may interfere with UDCA absorption or activity. Always inform your doctor about all medications you’re taking.\n\nQ5. How long does it take to see results?\nLiver function improvement can often be observed within a few weeks, but gallstone dissolution may take several months of consistent use.\n\nConclusion\n\nUrsodeoxycholic Acid 600 mg is a trusted and clinically validated therapy for various liver and gallbladder conditions. Its unique ability to enhance bile flow, protect liver cells, and dissolve cholesterol gallstones makes it an indispensable part of hepatology treatment protocols.", "price": 1385.0, "discountamount": 415.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2195, "imageuri": "https://productimages.withfloats.com/actual/69099314f017379146dfffdc.png", "tileimageuri": "https://productimages.withfloats.com/tile/69099314f017379146dfffdc.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-11-03T07:18:55.866Z", "updatedon": "2026-03-12T11:04:38.325Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//ursodeoxycholic-acid-600-mg/2195", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "UDCHOLIC 600 SR", "category": "GASTROLOGYRANGE", "tags": [ "ursodeoxycholic acid 600 mg", "ursodeoxycholic acid tablets 600 mg", "ursodeoxycholic acid 600 mg uses", "ursodeoxycholic acid 600 mg dosage", "what is ursodeoxycholic acid 600 mg", "how ursodeoxycholic acid works", "ursodeoxycholic acid used for liver disease", "ursodeoxycholic acid for gallstones treatment", "ursodeoxycholic acid benefits for liver", "ursodeoxycholic acid for fatty liver", "ursodeoxycholic acid 600 mg price in india", "ursodeoxycholic acid 600 mg tablet brands", "buy ursodeoxycholic acid 600 mg online", "best ursodeoxycholic acid tablets 600 mg", "what is ursodeoxycholic acid 600 mg used for", "how long to take ursodeoxycholic acid", "does ursodeoxycholic acid cure fatty liver" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "666992b14722330554e8f71b", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Foxetine 20 ", "description": "Foxetine 20 \nFluoxetine (20mg)\nIntroduction:\n\nFoxetine 20 contains Fluoxetine (20mg), a selective serotonin reuptake inhibitor (SSRI) commonly used to treat major depressive disorder, obsessive-compulsive disorder (OCD), panic disorder, and certain eating disorders. Fluoxetine is known for its efficacy in improving mood, sleep, appetite, and energy levels while reducing anxiety and unwanted thoughts.\nKey Features and Benefits:\n\nAntidepressant Properties: Fluoxetine is effective in treating the core symptoms of depression, including persistent sadness, loss of interest in activities, changes in appetite or weight, sleep disturbances, fatigue, and feelings of worthlessness or guilt.\nAnxiolytic Effects: It helps alleviate symptoms of anxiety, including excessive worry, restlessness, irritability, and difficulty concentrating, thereby improving overall mood and emotional well-being.\nObsessive-Compulsive Disorder (OCD): Fluoxetine is effective in reducing the frequency and severity of obsessive-compulsive behaviors and thoughts.\nPanic Disorder: It helps reduce the frequency and intensity of panic attacks and anxiety associated with panic disorder.\nBulimia Nervosa: Fluoxetine is approved for the treatment of bulimia nervosa, helping to reduce binge-eating and purging behaviors.\nSelective Serotonin Reuptake Inhibition: By selectively inhibiting the reuptake of serotonin in the brain, Fluoxetine increases the levels of this neurotransmitter, which plays a crucial role in mood regulation and emotional stability.\nDosage and Administration:\n\nInitial Dosage: The typical starting dose of Foxetine 20 (Fluoxetine 20mg) is once daily, preferably taken in the morning with or without food.\nDosage Adjustment: Your healthcare provider may adjust the dosage based on your response to treatment and individual needs. It's important to follow your doctor's instructions regarding dose changes.\nMaximum Dosage: The maximum recommended daily dose of Fluoxetine varies depending on the condition being treated but is generally up to 80mg per day for adults.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW \nhttps://www.sterisonline.com/product/foxetine-20-133574", "price": 38.3, "discountamount": 11.49, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "OCD", "day", "loss", "food", "SSRI", "EMAIL", "brain", "guilt", "adults", "doctor", "weight", "to 80mg", "anxiety", "morning", "fatigue", "feelings", "Benefits", "appetite", "response", "Foxetine", "interest", "severity", "efficacy", "frequency", "intensity", "treatment", "condition", "activities", "difficulty", "depression", "information", "irritability", "binge-eating", "instructions", "sterispharma", "restlessness", "sterisonline", "Introduction", "Key Features", "dose changes", "crucial role", "overall mood", "core symptoms", "CALL/WHATSAPP", "energy levels", "panic attacks", "worthlessness", "Administration", "panic disorder", "Initial Dosage", "Maximum Dosage", "Bulimia Nervosa", "excessive worry", "Fluoxetine 20mg", "mood regulation", "individual needs", "eating disorders", "neurotransmitter", "Dosage Adjustment", "unwanted thoughts", "Anxiolytic Effects", "persistent sadness", "sleep disturbances", "emotional stability", "healthcare provider", "emotional well-being", "typical starting dose", "Antidepressant Properties", "major depressive disorder", "obsessive-compulsive disorder", "obsessive-compulsive behaviors", "maximum recommended daily dose", "selective serotonin reuptake inhibitor", "Selective Serotonin Reuptake Inhibition" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1833, "imageuri": "https://productimages.withfloats.com/actual/666992b5475de163fe8e9bce.png", "tileimageuri": "https://productimages.withfloats.com/tile/666992b5475de163fe8e9bce.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-12T12:21:05.245Z", "updatedon": "2026-03-12T10:11:30.395Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//foxetine-20-/1833", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Foxetine 20 ", "category": "NEUROLOGY RANGE", "tags": [ "prolax capsules fluoxetine 20mg", "Fluoxetine (20mg)", "", "fluoxetine 20 mg side effects", "fluoxetine 20 mg uses", "fluoxetine side effects in females" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }